PRAC meeting highlights 4-7 March 2024

The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) is responsible for assessing and monitoring safety issues for human medicines.

The current PRAC highlights from the March 2024 meeting describes the insufficient evidence to establish a causal association between the COVID-19 vaccines Comirnaty and Spikevax and cases of postmenopausal bleeding.